Document Type : Original Research Article
Authors
1
Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
2
Department of Hematology-Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
3
Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Department of Management Sciences and Health Economics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.
4
Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
5
Mashhad University of Medical Sciences, School of Medicine, Mashhad, Iran
6
Babol University of Medical Sciences, School of Medicine, Babol, Iran
7
Pharmacotherapy
10.22038/ajp.2025.26317
Abstract
Objective: The aim of the present study is to evaluate the effectiveness of oral formulation of nano-curcumin in prevention of some chemotherapy-induced adverse reactions.
Materials and Methods: In this study, 84 patients with metastatic colorectal cancer were randomly assigned into the nano-curcumin (40 mg capsule) or placebo groups, receiving treatments three times daily, beginning the first day to the end of the sixth cycle of chemotherapy. To investigate various adverse events, including hematologic adverse reactions, diarrhea, hand-foot syndrome (HFS) and neuropathy, the criteria of National Cancer Institute Common Terminology for Adverse Events (NCI-CTCAE) version 5 were implemented after the third and sixth course.
Results: The CTCAE peripheral neuropathy score was significantly different between the two groups at the end of the 6th course (p=0.029) but not the third course (p=0.157). No significant response was observed for neutropenia, anemia, thrombocytopenia, HFS, or diarrhea at the end of both third (P=0.267, 0.258, 0.933, 0.377, and 0.811, respectively) and 6th courses (p=0.456, 0.645, 0.772, 0.34, and 0.114, respectively).
Conclusion: Nano-curcumin in dose of 40 mg thrice daily was not effective in prevention of neuropathy, HFS and hematologic adverse reactions induced by XELOX/FOLFOX-6 regimens. Further research with larger sample size on different nano-curcumin dosing schedules is suggested.
Keywords
Main Subjects
)